Literature DB >> 29624087

What does meaningful look like? A qualitative study of patient engagement at the Pan-Canadian Oncology Drug Review: perspectives of reviewers and payers.

Linda Rozmovits1, Helen Mai2, Alexandra Chambers2, Kelvin Chan3,4.   

Abstract

Objectives While there is wide support for patient engagement in health technology assessment, determining what constitutes meaningful (as opposed to tokenistic) engagement is complex. This paper explores reviewer and payer perceptions of what constitutes meaningful patient engagement in the Pan-Canadian Oncology Drug Review process. Methods Qualitative interview study comprising 24 semi-structured telephone interviews. A qualitative descriptive approach, employing the technique of constant comparison, was used to produce a thematic analysis. Results Submissions from patient advocacy groups were seen as meaningful when they provided information unavailable from other sources. This included information not collected in clinical trials, information relevant to clinical trade-offs and information about aspects of lived experience such as geographic differences and patient and carer priorities. In contrast, patient submissions that relied on emotional appeals or lacked transparency about their own methods were seen as detracting from the meaningfulness of patient engagement by conflating health technology assessment with other functions of patient advocacy groups such as fundraising or public awareness campaigns, and by failing to provide credible information relevant to deliberations. Conclusions This study suggests that misalignment of stakeholder expectations remains an issue even for a well-regarded health technology assessment process that has promoted patient engagement since its inception. Support for the technical capacity of patient groups to participate in health technology assessment is necessary but not sufficient to address this issue fully. There is a fundamental tension between the evidence-based nature of health technology assessment and the experientially oriented culture of patient advocacy. Divergent notions of what constitutes evidence and how it should be used must also be addressed.

Entities:  

Keywords:  Pan-Canadian Oncology Drug Review; health technology assessment; oncology drug funding; patient engagement

Mesh:

Substances:

Year:  2018        PMID: 29624087     DOI: 10.1177/1355819617750686

Source DB:  PubMed          Journal:  J Health Serv Res Policy        ISSN: 1355-8196


  4 in total

1.  Co-construction of health technology assessment recommendations with patients: An example with cardiac defibrillator replacement.

Authors:  Marie-Pascale Pomey; Philippe Brouillard; Isabelle Ganache; Laurie Lambert; Lucy Boothroyd; Caroline Collette; Sylvain Bédard; Alexandre Grégoire; Sandra Pelaez; Olivier Demers-Payette; Mireille Goetghebeur; Michèle de Guise; Denis Roy
Journal:  Health Expect       Date:  2019-11-05       Impact factor: 3.377

Review 2.  Reinforcing Collaboration and Harmonization to Unlock the Potentials of Advanced Therapy Medical Products: Future Efforts Are Awaited From Manufacturers and Decision-Makers.

Authors:  Tingting Qiu; Shuyao Liang; Yitong Wang; Claude Dussart; Borislav Borissov; Mondher Toumi
Journal:  Front Public Health       Date:  2021-11-25

3.  Integrating health technology assessment and the right to health: a qualitative content analysis of procedural values in South African judicial decisions.

Authors:  Michael J DiStefano; Safura Abdool Karim; Carleigh B Krubiner
Journal:  Health Policy Plan       Date:  2022-05-12       Impact factor: 3.547

4.  Engaging Patients in the Canadian Real-World Evidence for Value in Cancer Drugs (CanREValue) Initiative: Processes and Lessons Learned.

Authors:  William K Evans; Pam Takhar; Valerie McDonald; Martine Elias; Louise Binder; Stéphanie Michaud; Mina Tadrous; Caroline Muñoz; Kelvin K W Chan
Journal:  Curr Oncol       Date:  2022-08-07       Impact factor: 3.109

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.